Diabetic nephropathy: From mechanisms to rational therapies

Minerva Medica

Volumn 97, Issue 3, 2006, Pages 241-262

  Giunti, S ^a   Barit, D ^a   Cooper, Mark E ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

Advanced glycation end products; Angiotensin II; Diabetic nephropathy; Endothelin 1; Urotensin II

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ALAGEBRIUM; ALDOSTERONE ANTAGONIST; ALT 946; AMINOGUANIDINE; AMLODIPINE; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN RECEPTOR ANTAGONIST; EPLERENONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; MINERALOCORTICOID ANTAGONIST; PYRIDOXAMINE; RUBOXISTAURIN; SULODEXIDE; TELMISARTAN; THIAZOLIDINE DERIVATIVE; TRANILAST; UNCLASSIFIED DRUG; VALSARTAN;

APOPTOSIS; BLOOD PRESSURE; CLINICAL TRIAL; CULTURAL ANTHROPOLOGY; DIABETIC NEUROPATHY; DIET RESTRICTION; DISEASE COURSE; DOWN REGULATION; DRUG MECHANISM; DYSLIPIDEMIA; ENVIRONMENTAL FACTOR; FOLLOW UP; GENETIC SUSCEPTIBILITY; GLYCATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KELOID; KIDNEY DISEASE; KIDNEY FAILURE; META ANALYSIS; MICROANGIOPATHY; MONOTHERAPY; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PODOCYTE; PROTEIN RESTRICTION; RENAL PROTECTION; REVIEW; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW;

ANGIOTENSIN II; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ENDOTHELIN-1; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; HYPERTENSION; PROTEIN KINASE C; UROTENSINS;

EID: 33749261422     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (150)

1. U.S. Renal Data System. USRDS 2004 Annual Data Report. Atlas of End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004.
2. Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004;15 Suppl 1:S25-9.
3. Cooper ME. Pathogenesis, prevention and treatment of diabetic nephropathy. Lancet 1998;352:213-9.
4. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001;414:813-20.
5. Cooper ME, Jandeleit-Dahm K, Thomas MC. Targets to retard the progression of diabetic nephropathy. Kidney Int 2005;68:1439-45.
6. Hovind P, Tarnow L, Rossing P, Jensen BR, Graae M, Torp I et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004;328:1105.
7. Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. Am J Med 1982;72:375-80.
8. Mogensen CE. Renal function changes in diabetes. Diabetes 1976;25:872-9.
9. Hansen KW, Poulsen PL, Mogensen CE. Ambulatory blood pressure and abnormal albuminuria in type 1 diabetic patients. Kidney Int Suppl 1994;45:S134-40.
10. Pagtalunan ME, Miller PL, Jumping-Eagle S, Nelson RG, Myers BD, Rennke HG et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997;99:342-8.
11. Andersen AR, Christiansen JS, Andersen JK, Kreiner S, Deckert T. Diabetic nephropathy in Type 1 (insulin-dependent) diabetes: an epidemiological study. Diabetologia 1983;25:496-501.
12. Bojestig M, Arnqvist HJ, Hermansson G, Karlberg BE, Ludvigsson J. Declining incidence of nephropathy in insulin-dependent diabetes mellitus. N Engl J Med 1994;330:15-8.
13. Hovind P, Tarnow L, Rossing K, Rossing P, Eising S, Larsen N et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003;26:1258-64.
14. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003;348:2285-93.
15. Spijkerman AM, Dekker JM, Nijpels G, Adriaanse MC, Kostense PJ, Ruwaard D et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the hoorn screening study. Diabetes Care 2003;26:2604-8.
16. Mogensen CE, Chachati A, Christensen CK, Close CF, Deckert T, Hommel E et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1985;9:85-95.
17. Mauer SM, Steffes MW, Ellis EN, Sutherland DE, Brown DM, Goetz FC. Structural-functional relationships in diabetic nephropathy. J Clin Invest 1984;74:1143-55.
18. Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B et al. Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 1996;39:1569-76.
19. Wolf G, Chen S, Ziyadeh FN. From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy. Diabetes 2005;54:1626-34.
20. White KE, Bilous RW, Marshall SM, El Nahas M, Remuzzi G, Piras G et al. Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes 2002;51:3083-9.
21. Dalla Vestra M, Masiero A, Roiter AM, Sailer A, Crepaldi G, Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes 2003;52:1031-5.
22. Berg UB, Torbjornsdotter TB, Jaremko G, Thalme B. Kidney morphological changes in relation to long-term renal function and metabolic control in adolescents with IDDM. Diabetologia 1998;41:1047-56.
23. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes 2003;52:1023-30.
24. Bonnet F, Cooper ME, Kawachi H, Allen TJ, Boner G, Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001;44:874-7.
25. Davis BJ, Forbes JM, Thomas MC, Jerums G, Burns WC, Kawachi H et al. Superior renoprotective effects of combination therapy with ACE and AGE inhibition in the diabetic spontaneously hypertensive rat. Diabetologia 2004;47:89-97.
26. Thomas MC, Burns WC, Cooper ME. Tubular changes in early diabetic nephropathy. Adv Chronic Kidney Dis 2005;12:177-86.
27. Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 1999;56:1627-37.
28. Dalla Vestra M, Saller A, Bortoloso E, Mauer M, Fioretto P. Structural involvement in type 1 and type 2 diabetic nephropathy. Diabetes Metab 2000;26 Suppl 4:8-14.
29. Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 1993;43:661-7.
30. Thomas MC, Forbes JM, Cooper ME. Advanced glycation end products and diabetic nephropathy. Am J Ther 2005;12:562-72.
31. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994;43:676-83.
32. Berg TJ, Clausen JT, Torjesen PA, Dahl-Jorgensen K, Bangstad HJ, Hanssen KF. The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 1998;21:1997-2002.
33. Soulis T, Cooper ME, Vranes D, Bucala R, Jerums G. Effects of aminoguanidine in preventing experimental diabetic nephropathy are related to the duration of treatment. Kidney Int 1996;50:627-34.
34. Tanji N, Markowitz GS, Fu C, Kislinger T, Taguchi A, Pischetsrieder M et al. Expression of advanced glycation end products and their cellular receptor RAGE in diabetic nephropathy and nondiabetic renal disease. J Am Soc Nephrol 2000;11:1656-66.
35. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A 1994;91:11704-8.
36. Yamamoto Y, Kato I, Doi T, Yonekura H, Ohashi S, Takeuchi M et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest 2001;108:261-8.
37. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S et al. Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia. 2001;44:108-14.
38. Zhou G, Li C, Cai L. Advanced glycation end-products induce connective tissue growth factor-mediated renal fibrosis predominantly through transforming growth factor beta-independent pathway. Am J Pathol 2004;165:2033-43.
39. McLennan SV, Martell SK, Yue DK. Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 2002;51:2612-8.
40. Brizzi MF, Dentelli P, Rosso A, Calvi C, Gambino R, Cassader M et al. RAGE- and TGF-beta receptor-mediated signals converge on STAT5 and p21waf to control cell-cycle progression of mesangial cells: a possible role in the development and progression of diabetic nephropathy. Faseb J 2004;18:1249-51.
41. Wendt TM, Tanji N, Guo J, Kislinger TR, Qu W, Lu Y et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003;162:1123-37.
42. Li JH, Wang W, Huang XR, Oldfield M, Schmidt AM, Cooper ME et al. Advanced glycation end products induce tubular epithelial-myofibroblast transition through the RAGE-ERK1/2 MAP kinase signaling pathway. Am J Pathol 2004;164:1389-97.
43. Oldfield MD, Bach LA, Forbes JM, Nikolic-Paterson D, McRobert A, Thallas V et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001;108:1853-63.
44. Leehey DJ, Singh AK, Alavi N, Singh R. Role of angiotensin II in diabetic nephropathy. Kidney Int Suppl 2000;77:S93-8.
45. Hollenberg NK, Price DA, Fisher ND, Lansang MC, Perkins B, Gordon MS et al. Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. Kidney Int 2003;63:172-8.
46. Zimpelmann J, Kumar D, Levine DZ, Wehbi G, Imig JD, Navar LG et al. Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney Int 2000;58:2320-30.
47. Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004;66:2137-47.
48. Nicholas SB, Mauer M, Basgen JM, Aguiniga E, Chon Y. Effect of angiotensin II on glomerular structure in streptozotocin-induced diabetic rats. Am J Nephrol 2004;24:549-56.
49. Cooper ME, Allen TJ, Macmillan PA, Clarke BE, Jerums G, Doyle AE. Enalapril retards glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia 1989;32:326-8.
50. Kagami S, Border WA, Miller DE, Noble NA. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994;93:2431-7.
51. Ruiz-Ortega M, Bustos C, Hernandez-Presa MA, Lorenzo O, Plaza JJ, Egido J. Angiotensin II participates in mononuclear cell recruitment in experimental immune complex nephritis through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 synthesis. J Immunol 1998;161:430-9.
52. Gruden G, Thomas S, Burt D, Zhou W, Chusney G, Gnudi L et al. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells. J Am Soc Nephrol 1999;10:730-7.
53. Macconi D, Abbate M, Morigi M, Angioletti S, Mister M, Buelli S et al. Permselective dysfunction of podocytepodocyte contact upon angiotensin ii unravels the molecular target for renoprotective intervention. Am J Pathol 2006;168:1073-85.
54. Hoffmann S, Podlich D, Hahnel B, Kriz W, Gretz N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol 2004;15:1475-87.
55. Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, Gandhi NK et al. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant 2005;20:1320-8.
56. Wolf G, Ziyadeh FN. Renal tubular hypertrophy induced by angiotensin II. Semin Nephrol 1997;17:448-54.
57. Lan HY. Tubular epithelial-myofibroblast transdifferentiation mechanisms in proximal tubule cells. Curr Opin Nephrol Hypertens 2003;12:25-9.
58. Thomas MC, Tikellis C, Burns WM, Bialkowski K, Cao Z, Coughlan MT et al. Interactions between renin angiotensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005;16:2976-84.
59. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 1999;401:282-6.
60. Douglas SA, Dhanak D, Johns DG. From 'gills to pills': urotensin-II as a regulator of mammalian cardiorenal function. Trends Pharmacol Sci 2004;25:76-85.
61. Song W, Abdel-Razik AE, Lu W, Ao Z, Johns DG, Douglas SA et al. Urotensin II and renal function in the rat. Kidney Int 2006;69:1360-8.
62. Langham RG, Kelly DJ, Gow RM, Zhang Y, Dowling JK, Thomson NM et al. Increased expression of urotensin II and urotensin II receptor in human diabetic nephropathy. Am J Kidney Dis 2004;44:826-31.
63. Zhang AY, Chen YF, Zhang DX, Yi FX, Qi J, Andrade-Gordon P et al. Urotensin II is a nitric oxide-dependent vasodilator and natriuretic peptide in the rat kidney. Am J Physiol Renal Physiol 2003;285:F792-8.
64. Clozel M, Binkert C, Birker-Robaczewska M, Boukhadra C, Ding SS, Fischli W et al. Pharmacology of the urotensin-II receptor antagonist palosuran (ACT-058362; 1-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl- quinolin-4-yl) -urea sulfate salt): first demonstration of a pathophysiological role of the urotensin System. J Pharmacol Exp Ther 2004;311:204-12.
65. Totsune K, Takahashi K, Arihara Z, Sone M, Ito S, Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci (Lond) 2003;104:1-5.
66. Totsune K, Takahashi K, Arihara Z, Sone M, Murakami O, Ito S et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 2004;25:1809-14.
67. Clozel M, Hess P, Qiu C, Ding SS, Rey M. The urotensin-II receptor antagonist palosuran improves pancreatic and renal function in diabetic rats. J Pharmacol Exp Ther 2006;316:1115-21.
68. Benigni A, Colosio V, Brena C, Bruzzi I, Bertani T, Remuzzi G. Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes. Diabetes 1998;47:450-6.
69. Deuther-Conrad W, Franke S, Henle T, Sommer M, Stein G. In vitro-prepared advanced glycation end-products and the modulating potential of their low-molecular weight degradation products in IRPTC-A rat proximal-tubular derived kidney epithelial cell line. Cell Mol Biol (Noisy-le-grand) 2001;47 Online Pub: OL187-96.
70. Fukui M, Nakamura T, Ebihara I, Osada S, Tomino Y, Masaki T et al. Gene expression for endothelins and their receptors in glomeruli of diabetic rats. J Lab Clin Med 1993;122:149-56.
71. Shin SJ, Lee YJ, Lin SR, Tan MS, Lai YH, Tsai JH. Decrease of renal endothelin 1 content and gene expression in diabetic rats with moderate hyperglycemia. Nephron 1995;70:486-93.
72. Hocher B, Thone-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997;99:1380-9.
73. Hocher B, Schwarz A, Reinbacher D, Jacobi J, Lun A, Priem F et al. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001;87:161-9.
74. Pfab T, Thone-Reineke C, Theilig F, Lange I, Witt H, Maser-Gluth C et al. Diabetic endothelin B receptor-deficient rats develop severe hypertension and progressive renal failure. J Am Soc Nephrol 2006;17:1082-9.
75. Kelly DJ, Skinner SL, Gilbert RE, Cox AJ, Cooper ME, Wilkinson-Berka JL. Effects of endothelin or angiotensin II receptor blockade on diabetes in the transgenic (mRen-2)27 rat. Kidney Int 2000;57:1882-94.
76. Ortmann J, Amann K, Brandes RP, Kretzler M, Munter K, Parekh N et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension 2004;44:974-81.
77. Tsiani E, Lekas P, Fantus IG, Dlugosz J, Whiteside C. High glucose-enhanced activation of mesangial cell p38 MAPK by ET-1, ANG II, and platelet-derived growth factor. Am J Physiol Endocrinol Metab 2002;282:E161-9.
78. Hua H, Goldberg HJ, Fantus IG, Whiteside CI. High glucose-enhanced mesangial cell extracellular signal-regulated protein kinase activation and alpha1(IV) collagen expression in response to endothelin-1: role of specific protein kinase C isozymes. Diabetes 2001;50: 2376-83.
79. Gomez-Garre D, Ruiz-Ortega M, Ortego M, Largo R, Lopez-Armada MJ, Plaza JJ et al. Effects and interactions of endothelin-1 and angiotensin II on matrix protein expression and synthesis and mesangial cell growth. Hypertension 1996;27:885-92.
80. Ron D, Kazanietz MG. New insights into the regulation of protein kinase C and novel phorbol ester receptors. Faseb J 1999;13:1658-76.
81. Gruden G, Zonca S, Hayward A, Thomas S, Maestrini S, Gnudi L et al. Mechanical stretch-induced fibronectin and transforming growth factor-beta1 production in human mesangial cells is p38 mitogen-activated protein kinase-dependent. Diabetes 2000;49:655-61.
82. Weiss RH, Ramirez A. TGF-beta- and angiotensin-II-induced mesangial matrix protein secretion is mediated by protein kinase C. Nephrol Dial Transplant 1998;13:2804-13.
83. Koya D, Jirousek MR, Lin YW, Ishii H, Kuboki K, King GL. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997;100:115-26.
84. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996;272:728-31.
85. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M et al. Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 2004;53:2921-30.
86. Kapor-Drezgic J, Zhou X, Babazono T, Dlugosz JA, Hohman T, Whiteside C. Effect of high glucose on mesangial cell protein kinase C-delta and -epsilon is polyol pathway-dependent. J Am Soc Nephrol 1999;10:1193-203.
87. Goldberg HJ, Whiteside CI, Fantus IG. The hexosamine pathway regulates the plasminogen activator inhibitor-1 gene promoter and Sp1 transcriptional activation through protein kinase C-beta I and -delta. J Biol Chem 2002;277:33833-41.
88. Ha H, Yu MR, Choi YJ, Lee HB. Activation of protein kinase c-delta and c-epsilon by oxidative stress in early diabetic rat kidney. Am J Kidney Dis 2001;38:S204-7.
89. Xia P, Inoguchi T, Kern TS, Engerman RL, Oates PJ, King GL. Characterization of the mechanism for the chronic activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 1994;43:1122-9.
90. Osicka TM, Yu Y, Panagiotopoulos S, Clavant SP, Kiriazis Z, Pike RN et al. Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C. Diabetes 2000;49:87-93.
91. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001;44:1957-72.
92. Toyoda M, Suzuki D, Honma M, Uehara G, Sakai T, Umezono T et al. High expression of PKC-MAPK pathway mRNAs correlates with glomerular lesions in human diabetic nephropathy. Kidney Int 2004;66:1107-14.
93. Studer RK, Craven PA, DeRubertis FR. Role for protein kinase C in the mediation of increased fibronectin accumulation by mesangial cells grown in high-glucose medium. Diabetes 1993;42:118-26.
94. Hayashida T, Schnaper HW. High ambient glucose enhances sensitivity to TGF-betal via extracellular signal: regulated kinase and protein kinase Cdelta activities in human mesangial cells. J Am Soc Nephrol 2004;15:2032-41.
95. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003;14:S241-5.
96. Kitada M, Koya D, Sugimoto T, Isono M, Araki S, Kashiwagi A et al. Translocation of glomerular p47phox and p67phox by protein kinase C-beta activation is required for oxidative stress in diabetic nephropathy. Diabetes 2003;52:2603-14.
97. Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes 1998;47:859-66.
98. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S et al. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. Faseb J 2000;14:439-47.
99. Kelly DJ, Chanty A, Gow RM, Zhang Y, Gilbert RE. Protein kinase Cbeta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 2005;16:1654-60.
100. Menne J, Park JK, Boehne M, Elger M, Lindschau C, Kirsch T et al. Diminished loss of proteoglycans and lack of albuminuria in protein kinase C-alpha-deficient diabetic mice. Diabetes 2004;53:2101-9.
101. The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. Kidney Int 1995;47:1703-20.
102. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
103. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
104. Microalbuminuria Collaborative Study Group. Intensive therapy and progression to clinical albuminuria in patients with insulin dependent diabetes mellitus and microalbuminuria. BMJ 1995;311:973-7.
105. Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23 Suppl 2:B21-29.
106. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000;36:646-61.
107. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81.
108. American Diabetes Association. Diabetic nephropathy. Diabetes Care 1999;22:S66-9.
109. Sawicki PT, Heise T, Berger M. Antihypertensive treatment and mortality in diabetic patients. What is the evidence? Diabetologia 1997;40 Suppl 2:S134-7.
110. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-72.
111. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.
112. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
113. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
114. The ACE Inhibitors in Diabetic nephropathy Trialist group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001;134:370-9.
115. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH. Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000;57:601-6.
116. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
117. Viberti G, Wheeldon NM. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002;106:672-8.
118. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.
119. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004;351:1952-61.
120. Allen TJ, Cao Z, Youssef S, Hulthen UL, Cooper ME. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Diabetes 1997;46:1612-8.
121. Lacourciere Y, Belanger A, Godin C, Halle JP, Ross S, Wright N et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762-9.
122. Cao Z, Bonnet F, Davis B, Allen TJ, Cooper ME. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats. Clin Sci (Lond) 2001;100:591-9.
123. Rossing K, Jacobsen P, Pietraszek L, Parving HH. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial. Diabetes Care 2003;26:2268-74.
124. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117-24.
125. Epstein M. Aldosterone as a mediator of progressive renal disease: pathogenetic and clinical implications. Am J Kidney Dis 2001;37:677-88.
126. Hostetter TH, Rosenberg ME, Ibrahim HN, Juknevicius I. Aldosterone in progressive renal disease. Semin Nephrol 2001;21:573-9.
127. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003;41:64-8.
128. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21.
129. Hansen HP, Tauber-Lassen E, Jensen BR, Parving HH. Effect of dietary protein restriction on prognosis in patients with diabetic nephropathy. Kidney Int 2002;62:220-8.
130. Lassila M, Seah KK, Allen TJ, Thallas V, Thomas MC, Candido R et al. Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products. J Am Soc Nephrol 2004;15:2125-38.
131. Bonnet F, Cooper ME. Potential influence of lipids in diabetic nephropathy: insights from experimental data and clinical studies. Diabetes Metab 2000;26:254-64.
132. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-low-ering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
133. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61.
134. Yamada H, Tajima S, Nishikawa T, Murad S, Pinnell SR. Tranilast, a selective inhibitor of collagen synthesis in human skin fibroblasts. J Biochem (Tokyo) 1994;116:892-7.
135. Holmes DR Jr, Savage M, LaBlanche JM, Grip L, Serruys PW, Fitzgerald P et al. Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 2002;106:1243-50.
136. Mifsud S, Kelly DJ, Qi W, Zhang Y, Pollock CA, Wilkinson-Berka JL et al. Intervention with tranilast attenuates renal pathology and albuminuria in advanced experimental diabetic nephropathy. Nephron Physiol 2003;95:p83-91.
137. Soma J, Sugawara T, Huang YD, Nakajima J, Kawamura M. Tranilast slows the progression of advanced diabetic nephropathy. Nephron 2002;92:693-8.
138. Campochiaro PA. Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 2004;45:922-31.
139. Turtle KR, Bakris GL, Toto RD, McGill JB, Hu K, Anderson PW. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005;28:2686-90.
140. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozodn-induced diabetic rat. Diabetes 1991;40:1328-34.
141. Degenhardt TP, Alderson NL, Arrington DD, Beattie RJ, Basgen JM, Steffes MW et al. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 2002;61:939-50.
142. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S et al. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 1999;42:579-88.
143. Vasan S, Foiles P, Founds H. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks. Arch Biochem Biophys 2003;419:89-96.
144. Forbes JM, Thallas V, Thomas MC, Founds HW, Burns WC, Jerums G et al. The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. Faseb J 2003;17:1762-4.
145. Bolton WK, Cattran DC, Williams ME, Adler SG, Appel GB, Cartwright K et al. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 2004;24:32-40.
146. Gambaro G, Venturini AP, Noonan DM, Fries W, Re G, Garbisa S et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994;46:797-806.
147. Xu X, Rao G, Maxhimer JB, Prinz RA, Lewis EJ. Mechanism of action of sulodexide-mediated control of diabetic proteinuria: inhibition of heparanase-1 activity. J Am Soc Nephrol 2005;16:673A.
148. Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlova M, Olsovsky J et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 2002;13:1615-25.
149. Achour A, Kacem M, Dibej K, Skhiri H, Bouraoui S, El May M. One year course of oral sulodexide in the management of diabetic nephropathy. J Nephrol 2005;18:568-74.
150. Wenzel RR, Mann J, Jurgens C, Yildirim I, Bruck H, Philipp T et al. The ETA-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. J Am Soc Nephrol 2005;16:58A.